B + L, CROMA donate eye drops

Bausch + Lomb and CROMA have donated 50,000 units of bromfenac sodium sesquihydrate (Yellox) to projects in Africa sponsored by Light for the World.


Vienna-Bausch + Lomb (B + L), the global eye health company, and CROMA, a private global specialty pharmaceutical and surgical company, have donated 50,000 units of bromfenac sodium sesquihydrate (Yellox), a highly effective, non-steroidal anti-inflammatory drug (NSAID) for postoperative ocular inflammation following cataract extraction, to projects in Africa sponsored by Light for the World, an Austrian organization that supports people who have no access to ophthalmic care. These eye drops are vital for post-operative treatment of cataract patients.

”It is our social responsibility and commitment to support the improvement of vision in economically challenged regions of the world," said Mag. Gerhard Prinz, CEO of CROMA Pharma GmbH. “CROMA has been contributing to Light for the World for many years and we are proud to make a difference in improving health and quality of life.” 

“We are delighted to be able to support Light for the World in their effort to improve the sight of people in Africa,” said Calvin Roberts, MD, executive vice president and chief medical officer, B + L. “Proper post-operative care is the key to maximizing the surgery’s results–ultimately achieving the best possible outcome for the patient.”


For more articles in this issue of Ophthalmology Times eReport, click here.

Related Videos
New optics textbook aims to be a compendium resource for the topic
Visus Therapeutics CEO announces acquisition of ViewPoint Therapeutics to expand on cataract, presbyopia candidate
EyeCon 2022: Keeping updates in cataract and refractive surgery in focus
How quality vision builds a foundation for safety and everyday activities
Related Content
© 2023 MJH Life Sciences

All rights reserved.